A2M (Ars Accessus Medica) is headed by Mark Nuijten, PhD, MD, MBA, and Adjunct Professor at ITU. He is medical doctor, health economist, valuation economist, and healthcare journalist. Mark Nuijten has a varied career in pharma business. The extensive list of international co-authors, colleagues ,and co-workers on workshops and task forces over the past twenty years is truly impressive and reads like a who's who of health economics, including leading experts like John Hutton, Bryan Luce, Frans Rutten, Bengt Jonnsen, Mike Drummond, Matthias Graf Von der Schulenburg, and Robert Rubin.
Mark Nuijten has a varied career in pharma business. He has published and co-shared meetings and workshops with over the past twenty years is truly impressive and reads like a who's who of health economics, including leading experts like John Hutton, Bryan Luce, Frans Rutten, Bengt Jonnsen, Mike Drummond, Matthias Graf Von der Schulenburg, and Robert Rubin. Mark Nuijten is pursuing development of economic modelling and broadening its application in health care and finance. He is a pioneer in the field of healthcare innovation in biotechnology and nutrition, and has been the first classical health economist successfully applying and developing Discounted Cash Flow methodologies for valuation of biotechnology innovation. For example, developing a Pricing Matrix Model for research in early phase development and a Financial Valuation Algorithm for the assessment of the future sales of a new, innovative medicinal product. His models successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, NICE in England, SMC in Scotland, TLV in Sweden, and Zin in The Netherlands). He is academic supervisor of PhD programs at the Universities of Maastricht and Groningen in The Netherlands and founder of the ISPOR Special Interest Group on nutrition-economics. Since 2017 he is Adjunct Professor at ITU (Istanbul Technical University) in Turkey.
Prior to setting up A2M, Mark Nuijten was a partner with MEDTAP International. As a VP Business Development for Europe he established global Pricing and Reimbursement Consultancy Services for MEDTAP. Before MEDTAP, he was a Managing Director of the Quintiles office in the Netherlands.
Mark Nuijten trained as a physician and worked in clinical practice before obtaining an international M.B.A. from Erasmus University, Rotterdam, with a focus on financial management. He obtained his PhD in health economics (2003) on the thesis “In search of more confidence in health economic modelling” at the Erasmus University, Rotterdam. Mark Nuijten has become one of the top health economic experts over the last decade, reflected in more than 200 publications and leading positions in scientific societies and editorial boards. Mark Nuijten was Board Director of ISPOR (2002-2004) and Chair of the Management Board of Value in Health (2002-2004) and was honoured with the ISPOR 2003 - 2004 BOARD OF DIRECTORS SERVICE AWARD. He was member of the Editorial Advisory Board of Value in Health.
Mark Nuijten is founding member and A2M is owner of Minerva Health Economics Network, Ltd. (MINERVA) is a formal affiliation of independent health-economic consultancies and contract-research organizations strategically located in major markets with more than 200 staff members in the key pharmaceutical markets in Europe, US, Canada, Australia and Japan. (www.minerva-network.com). The members of MINERVA have a wealth of experience in the fields of health economics and outcomes research, as well as extensive knowledge of issues concerning international reimbursement and market access.
Minerva has built up a network of collaborators around the world, and has longstanding relationships with key clinical opinion leaders, as well as healthcare policy and decision makers, in all of the countries that are represented in the network. Minerva’s clientele encompasses virtually every pharmaceutical and biotechnology company in the US and Europe, as well as numerous medical device companies, health insurers, third-party payers, and governmental authorities, such as NICE, HAS, IFLN, WHO, and the World Bank. The individual members of Minerva collaborate on many projects, and the group’s rigorous and consistent approach to working ensures that all multinational studies benefit from native country-specific knowledge and expertise.
Minerva includes York Health Economics Consortium (UK) of the University of York, which is home to the largest and most active health economics department in the UK and leading academic center of health economics in the world with the principal founders of Health Economics as a new disciplne:Prof Micheal Drummond, Prof John Huton, and Prof Mark Sculpher.